OSA and T1D Version 1

  • Research type

    Research Study

  • Full title

    Obstructive Sleep Apnoea (OSA) in Patients with Type 1 Diabetes (T1D): A Cross-Sectional Study

  • IRAS ID

    209532

  • Contact name

    Abd A Tahrani

  • Contact email

    a.a.tahrani@bham.ac.uk

  • Duration of Study in the UK

    2 years, 0 months, 1 days

  • Research summary

    Obstructive sleep apnoea (OSA) is a very common condition which is characterised by recurrent episodes of upper airway (windpipe) obstruction resulting in recurrent episodes of hypoxaemia (drop in blood oxygen levels) and changes in blood pressure and heart rate during sleep. As a result, the patient gets recurrent episodes of stopping breathing during sleep and wakes up un-refreshed. Snoring and excessive daytime sleepiness are the two most common features of this condition. OSA is associated with increased risk of cardiovascular disease and road traffic accidents and impaired quality of life. In patients with Type 2 diabetes, OSA was found to be associated with the development and progression microvascular complications (i.e. eyes, kidney and nerve damage from diabetes). Little is known about OSA in patients with Type 1 diabetes, but with improved care patients with Type 1 diabetes are getting more obese and living longer. In addition, recent small studies suggested a high prevalence of OSA in patients with Type 1 diabetes although they were younger and leaner than patients with Type 2 diabetes, suggesting that factors other than obesity are contributing to the development of OSA in Type 1 diabetes. Hence, we aim to conduct a cross-sectional study of adult patients with Type 1 diabetes to assess the prevalence of OSA and to primarily examine the relationship between OSA and autonomic neuropathy (damage to the small nerve fibres in the heart and upper airways) as potential mechanism to the increased prevalence of OSA in patients with Type 1 diabetes. Patients will be recruited from Heart of England NHS Foundation Trust. Patients will be seen once at the research centre, where data regarding their Type 1 diabetes and its complications will be collected, and they will be screened for OSA.

  • REC name

    West Midlands - Edgbaston Research Ethics Committee

  • REC reference

    17/WM/0238

  • Date of REC Opinion

    12 Sep 2017

  • REC opinion

    Further Information Favourable Opinion